XOMA Co. (NASDAQ:XOMA) Major Shareholder Sells $13,069,366.20 in Stock

XOMA Co. (NASDAQ:XOMA - Get Free Report) major shareholder Bvf Partners L. P/Il sold 500,742 shares of the firm's stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $26.10, for a total value of $13,069,366.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.

XOMA Price Performance

XOMA stock traded up $0.35 during mid-day trading on Friday, hitting $26.61. 28,950 shares of the company were exchanged, compared to its average volume of 60,454. XOMA Co. has a 1-year low of $19.50 and a 1-year high of $35.00. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. The business has a fifty day moving average of $27.84 and a 200 day moving average of $28.09. The company has a market capitalization of $313.47 million, a PE ratio of -7.65 and a beta of 0.92.

XOMA (NASDAQ:XOMA - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.05. The firm had revenue of $7.20 million during the quarter, compared to the consensus estimate of $6.66 million. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. As a group, sell-side analysts expect that XOMA Co. will post -1.41 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on XOMA shares. HC Wainwright restated a "buy" rating and issued a $123.00 price objective on shares of XOMA in a research note on Tuesday, January 7th. StockNews.com raised shares of XOMA from a "sell" rating to a "hold" rating in a research report on Thursday, January 16th.

Institutional Investors Weigh In On XOMA

Large investors have recently bought and sold shares of the business. New York State Common Retirement Fund increased its position in XOMA by 51.2% in the 4th quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company's stock valued at $62,000 after acquiring an additional 800 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of XOMA by 18.1% in the fourth quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company's stock valued at $291,000 after purchasing an additional 1,699 shares in the last quarter. Barclays PLC raised its position in XOMA by 300.7% in the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company's stock worth $298,000 after purchasing an additional 8,447 shares during the last quarter. Geode Capital Management LLC lifted its holdings in XOMA by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company's stock worth $4,840,000 after buying an additional 1,138 shares in the last quarter. Finally, State Street Corp boosted its position in XOMA by 1.2% in the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company's stock valued at $3,783,000 after buying an additional 1,754 shares during the last quarter. 95.92% of the stock is currently owned by institutional investors.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.